drug
nipocalimab
pre_registrationupdated 5mo agoby $JNJ JOHNSON & JOHNSON
community read0 votes
indications
indications
Lupus
all catalysts(0)
nothing on the calendar yet
Trials studying nipocalimab
- phase3Nipocalimab in Moderate to Severe Sjogren's Disease
- phase3Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- phase3A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- phase3A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
- phase1A Study to Assess Nipocalimab Concentrations in Breast Milk of Healthy Lactating Women
- phase3Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
- phase3A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- phase3A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
News(7)
- 6 immunology targets to sustain a mammoth I&I marketJohnson & Johnson, Pfizer, Argenx and more are unlocking new immunology targets and looking to improve on existing ones in an attempt to catch some of the magic brought about by AbbVie’s Humira and…biospace · 6d ago
- Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trialA real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.biopharma_dive · 1mo ago
- J&J’s Imaavy wins label expansion; Two approvals in JapanJ&J’s Imaavy wins label expansion: The monoclonal antibody is now the first treatment approved specifically for warm autoimmune hemolytic anemia, a rare autoantibody disease that causes severe anem…endpoints · 1mo ago
- STAT+: Pharmalittle: We’re reading about RFK Jr. vaccine disclosures, a Merck loss over Medicare prices, and moreDemocratic senators said RFK Jr.'s recent explanation of how he disposed of a financial stake in Gardasil litigation conflicts with his earlier answersstat · 1mo ago
- Recon: FDA expands labels for J&J’s Imaavy, Jazz's Ziihera; Teva faces Turkish antitrust probe over patent movesWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 1mo ago
- Sensorion axes hearing loss program; Novartis' biomarker data in muscular dystrophyPlus, news about Imaavy. 👂 Sensorion selects one hearing loss program, axes another: The biotech is ending the development of SENS-501 for OTOF-related hearing loss following a “strategic review.”…endpoints · 3mo ago
- J&J looks to widen Imaavy’s use; $300M backs rare disease drug launchNew data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.biopharma_dive · 3mo ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that